SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
兩家公司承諾在未來12個月內爲全球20個機構提供尖端的液體活檢測試
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (NASDAQ:AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months.
波士頓和瑞士羅爾，2024年9月10日 /PRNewswire/ — 雲原生醫療保健技術公司、數據驅動醫學領域的全球領導者SopHia Genetics（納斯達克股票代碼：SOPH）今天宣佈了全球推出基於SopHia dDM的液體活檢測試msK-Access的新里程碑，該測試於2023年10月首次發佈。根據與阿斯利康（納斯達克股票代碼：AZN）簽訂的最終合作協議，SopHia GENETICS將在未來12個月內加快在全球20個地點部署由SopHia dDM提供支持的MSK-Access。
譯文內容由第三人軟體翻譯。